Conference Call Monday at 8:30 a.m. ET Expands Spectranetics' portfolio of solutions to treat complex vascular conditions in projected $ 700 million drug coated balloon segment COLORADO SPRINGS, Colo., and DUBLIN, Ireland, Nov. 2, 2014 -- The Spectranetics Corporation and Covidien plc today announced a definitive agreement under which Spectranetics will acquire Covidien's Stellarex drug coated angioplasty balloon platform for $30 million. The transaction is subject to approval by the Federal Trade Commission and other regulatory agencies, as well as closure of the pending acquisition of Covidien by Medtronic, which is expected to occur in early 2015.